Vascepa is a prescription medication that contains the active ingredient icosapent ethyl and is used to treat high levels of triglycerides in the blood. The drug is produced by Amarin Corporation and has been approved by the FDA since 2012. According to the sources provided, the cost of Vascepa without insurance can be quite expensive. A month's supply of Vascepa can cost around $300 [2]. However, the cost of Vascepa may decrease in the future as the drug's patent has expired. This means that generic versions of Vascepa may become available, which can be significantly cheaper than the brand-name version.

According to DrugPatentWatch, the patent for Vascepa expired in January 2020 [1]. This means that other pharmaceutical companies can now produce generic versions of the drug. It is expected that the introduction of generic Vascepa will significantly reduce the cost of the drug [1]. However, as of the time of writing, there are no generic versions of Vascepa available in the US market.

It is worth noting that generic versions of Vascepa have been approved in other countries. For example, Lixia Therapeutics has received approval for a generic version of Vascepa in China and the European Union [3]. The approval of generic Vascepa in these regions may lead to increased competition and lower prices for the drug.

In conclusion, while there are currently no generic versions of Vascepa available in the US market, the expiration of the drug's patent is expected to lead to the introduction of cheaper generic versions in the future. The cost of Vascepa without insurance can be quite expensive, but the introduction of generic versions may significantly reduce the cost of the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.singlecare.com/blog/vascepa-without-insurance/
[3] http://www.lyxia.com/vascepa-expands-the-european-union-and-china-market-allowing-epa-as-a-generic-drug/